ArticleFuture oncology (London, England)2025

Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.

Kevin Harrington et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.